Claudia is investigating the impact of RAS pathway inhibition on tumor-infiltrating lymphocyte (TIL) expansion and therapeutic efficacy using preclinical cancer models. She is also exploring how targeting metabolic pathways can enhance adoptive T-cell therapy.